A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Key Inclusion Criteria:

1. Must have measurable disease according to RECIST v1.1.

2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1.

3. Acceptable organ and bone marrow function.

4. Participant must have a life expectancy of at least 3 months.

Key Exclusion Criteria:

1. Has clinically significant toxicities from previous anticancer therapies.

2. Has rapidly progressing disease.

3. Has a history of noninfectious pneumonitis/interstitial lung disease.

4. Has a history of liver disease.

5. Has had an allogeneic tissue/solid organ transplant or autologous or allogeneic bonemarrow transplant, or stem cell rescue within 3 months prior to the first dose ofGEN1042.

6. Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, orprogressive brain metastases or stroke.

7. Has had major surgery within 4 weeks before Screening.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.